Head and Neck Squamous Cell Carcinoma (HNSCC) Recruiting Phase 2 Trials for Cetuximab (DB00002)

Also known as: Head and Neck Squamous Cell Carcinoma

IndicationStatusPhase
DBCOND0043665 (Head and Neck Squamous Cell Carcinoma (HNSCC))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02270814Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell CarcinomaTreatment
NCT03082534Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell CarcinomaTreatment
NCT03389477Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell CarcinomaTreatment